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ABSTRACT Partial amino acid sequence information al-
lowed the isolation of cDNA clones encoding the turkey
erythrocyte (3-adrenergic receptor. Antisera raised against
synthetic peptides encoded by the cDNA crossreacted with the
purified receptor and appropriate tryptic fragments, confirm-
ing the identity of the cDNA. The receptor is composed of 483
amino acids and has a molecular mass of 54 kDa. Its sequence
suggests that it is arranged predominantly in seven membrane-
spanning sequences and a long cytoplasmic carboxyl-terminal
domain. The extracellular amino-terminal domain contains a
consensus sequence for N-glycosylation. The /3-adrenergic
receptor displays overall structural similarity and weak se-
quence homology with rhodopsin. Because both proteins act by
regulating GTP-binding proteins, a compact structure based
on seven membrane-spanning regions may be a general model
for receptors that act on G proteins.
The f3-adrenergic receptor is probably the most intensely
studied of the many cell surface receptors that cause the
activation of adenylate cyclase. These receptors catalyze the
binding of GTP to a regulatory protein, G, on the inner face
of the plasma membrane, thereby activating it. Activated G,
can then bind to adenylate cyclase and stimulate its activity
(see ref. 1 for review). The ,B-adrenergic receptor is thus a
member of an even larger class of cell surface receptors that
regulate the functions of multiple GTP-binding regulatory
proteins, or G proteins. These proteins control the activation
or inhibition of adenylate cyclase and the activities of
phospholipases A2 and C, cyclic GMP phosphodiesterase,
and probably other signal transducing enzymes.
The ,-adrenergic receptor has been purified from a number
of tissues and has been shown to be a relatively hydrophobic,
integral plasma membrane glycoprotein (see ref. 1 for re-
view). The avian erythrocyte is an abundant source of
P3-adrenergic receptors, and the receptor from turkey eryth-
rocytes has been particularly well studied both in native
membranes and after its purification (1, 2). Its molecular
mass, =52 kDa (see ref. 1), is somewhat smaller than that of
the receptor isolated from mammalian tissues, although the
deglycosylated form of the mammalian receptor is closer to
that of birds (1). Functionally, the receptor is phylogeneti-
cally conserved. The receptor purified from turkey erythro-
cytes can efficiently regulate GO from rabbit liver in recon-
stituted phospholipid vesicles (3, 4), and its selectivity for
numerous agonist and antagonist ligands is only slightly
discrepant from the mammalian 31-adrenergic receptor (5).
Whether the receptor interacts with G. on the hydrophilic
cytoplasmic face of the plasma membrane or within the
bilayer is unknown; nor is anything known about the struc-
tural details of this regulatory interaction. Presumably, all
receptors that activate G proteins will share this regulatory
domain, and definable differences will exist in the homolo-
gous regions of receptors that activate different G proteins.
The sites of P-adrenergic ligand binding, regulatory phos-
phorylation, and stimulatory reduction by thiols (6) are also
of great interest. Much of the difficulty in learning about the
structure of the f3-adrenergic receptor is due to its low
concentration in plasma membranes: P-adrenergic receptor
must be purified over 20,000-fold from an already well-
purified plasma membrane fraction. We have therefore un-
dertaken the cloning of the cDNA that encodes the P-
adrenergic receptor as a first step toward more direct studies
of its structure and function. The sequence of the 82-
adrenergic receptor from hamster lung has appeared recently
(7), and homology between the two sequences and the
sequence of rhodopsin suggests functionally important as-
pects of their structures.
METHODS
P3-Adrenergic receptor was purified from turkey erythrocyte
plasma membrane as described by Brandt and Ross (4). This
preparation, which consists mainly of an active 40-kDa
proteolysis product and the 53-kDa receptor (1, 4), was
separated from digitonin and minor impurities by HPLC on
a 300-A pore size, C4 column (Synchrom, Linden, IN) using
a linear gradient of0.1% trifluoroacetic acid in water to 0.06%
trifluoroacetic acid in 50% 1-propanol (vol/vol). The receptor
was cleaved with cyanogen bromide, 60 mg/ml in 70%
(vol/vol) formic acid, for 24 hr at room temperature under
nitrogen. Sequencing was performed using a modified spin-
ning-cup sequencer (8), and primary amines were blocked (9)
in the sequencer with 0.2 ml of 30 mM o-phthalaldehyde in
butyl chloride.
Total poly(A)-containing RNA from red blood cells of
7-11-day fetal turkey was prepared (10, 11) and used to
construct a cDNA library (3.7 x 106 clones) (12) using vector
XgtlO (Vector Cloning System, San Diego, CA). A second
library was also prepared by priming with an oligonucleotide
based on the sequence of the XTE-5 clone (no. 3 in Fig. 3).
Synthetic probes (13) were labeled by 5' phosphorylation (14)
using T4 polynucleotide kinase (United States Biochemicals,
Cleveland, OH) and [y-32P]ATP. Complementary sequences
were synthesized using Escherichia coli DNA polymerase I
(Klenow fragment, Boehringer Mannheim) and [a-32P]dCTP
and [a-32P]dATP. This procedure yielded specific activities
of 3-6 x 108 cpm fitg1
Abbreviation: bp, base pair(s).
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FIG. 1. Sequences of peptides derived from the f-adrenergic
receptor. Peptide 1: HPLC-purified receptor (0.1 nmol) was applied
to the filter of a gas-phase protein sequencer and treated with
cyanogen bromide. Several amino termini were detected, and a
proline residue was found at cycle 6. Cyanogen bromide-treated
receptor (0.4 nmol) was applied to a spinning-cup sequencer and, at
cycle six, was exposed to o-phthalaldehyde, instead of phenylisothi-
ocyanate, in order to block primary amines but to spare proline
residues (9). Thereafter, a single sequence was obtained. Peptides 2
and 3: A separate cyanogen bromide digest (0.5 nmol) was dissolved
in 6 M guanidine-hydrochloride/0.1 M 2-mercaptoethanol/0.05 M
Tris HCl, pH 8.5, and chromatographed on a C4 column as described.
A fraction that was eluted as two closely spaced peaks contained a
6-kDa peptide having the sequence shown as peptide 2. The two
peaks may represent the homoserine and homoserine lactone forms
of the same peptide. X represents ambiguous residues. Another
fraction contained two peptides. One was evidently a cleavage
product of the other, which contained an internal methionine residue
at position three. The two overlapping sequences, shown as peptides
3a and b, could be read simultaneously. Peptides 4 and 5: A tryptic
digest (6-10 ,ug/ml; 14-24 hr at room.temperature) of the purified
receptor was fractionated by HPLC. Two fractions yielded the
sequences shown. Peptide 5 displayed a molecular mass of "49 kDa
by NaDodSO4/polyacrylamide gel electrophoresis.
Plaque hybridization was carried out at 42°C for 16 hr under
low stringency conditions: 20% (vol/vol) formamide, 5x SSC
(lx SSC = 0.15 M NaCl, 0.015 M cit, pH 7.0). Nucleotide
sequence analysis was carried out using pIBI (clones XTE-30,
XTE-5, XTE-A33, and Xte-6) or M13-based cloning vectors
(15-18). Both strands of all inserts were sequenced. The
upstream 300-base-pair (bp) sequence was obtained separate-
ly with six different clones.
Immunogenic peptides were coupled to soy trypsin inhib-
itor using maleimidobenzoyl-N-hydroxysuccinimide ester
(Pierce) and injected into rabbits s.c. and i.m. in complete
Freund's adjuvant. For immunoblots, samples' were electro-
phoresed on polyacrylamide gels (19). The gels were soaked
for 30 min at room temperature in 25 mM Tris/195 mM
glycine (pH 8.3), and proteins were electrophoretically trans-
ferred to'nitrocellulose in the same buffer (35 V; 1 hr).
Binding of antibody and detection using "25I-labeled antibody
to rabbit IgG were done according to Harris et al. (20).
RESULTS
Isolation of cDNA Clones. ,3-Adrenergic receptor purified
from turkey erythrocytes (5) was used to obtain the peptide
sequences necessary to design oligonucleotide probes for the
selection of cDNA clones. The amino, terminus of the
receptor was blocked to Edman degradation, but treatment
with cyanogen bromide or trypsin generated numerous pep-
tides, and four separate regions of the receptor were se-
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FIG. 3. cDNA inserts encoding the 3-adrenergic receptor. The
protein coding region is indicated by the stippled box. Boxes a and
b indicate probes based on amino acid sequences, the numbered
black boxes indicate other probes used for screening, and the white
box (number 3) represents the oligonucleotide used to prime a cDNA
library. Solid bars show individual cDNA inserts that were se-
quenced. Scale at top is in bp.
quenced (Fig. 1). -Peptide 1 was sequenced in an unfraction-
ated cyanogen bromide digest of the receptor. Fortuitously,
when the total digest was analyzed, a proline residue was
detected at cycle six. With a separate sample, we used
o-phthalaldehyde to block free primary amino groups after
the fifth cycle (9). Because a terminal proline residue will not
react with o-phthalaldehyde, this'reaction permitted the
continued sequence analysis of the unblocked, proline-
containing peptide. This sequence allowed the design of an
initial oligonucleotide probe (Fig. 2).
When the cDNA library was probed with two overlapping
33-mer'oligonucleotides based on the'sequence of peptide 1
(Fig. 2), four strongly hybridizing clones were isolated and
characterized by blot hybridization analysis (22, 23). The
cDNA inserts in all four clones measured 300-400 bp. Two
clones, XTE-5 and XTE-30 (Fig. 3), covered a 576-bp open
reading frame and shared a 144-bp overlap that contained a
sequence matching 17 of the 18 amino' acids in peptide 1.
Three more overlapping clones were sequentially selected
and sequenced using probes based on peptide 2 and on the 3'
ends of the subsequently isolated cDNA clones (Fig. 3). One
of these clones, XTE-D9, contained an in-frame stop codon
and, at the 3' end, a stretch of nine adenosines that is
preceded by a potential polyadenylylation site. To qxtend the
cDNA sequence upstream'of the 5' end of XTE-5, we
constructed a new cDNA library by priming with oligonu-
cleotide 3 (Fig. 3). All of the 32 independently isolated clones
from this new library terminated ""120 bp upstream from the
priming site, suggesting that this is the actual 5' end of the
mRNA.
Confirmation of Primary Structure.' Fig. 4 shows the
sequence of the cDNA carried by the clones shown in Fig. 3.
The longest open reading frame lies between the 5' end and
nucleotide 1518. Each of the five experimentally determined
peptide sequences shown in Fig. 1 is encoded by the cDNA.
To further confirm the identity of this cDNA as being that of
the ,B-adrenergic receptor, antibodies were raised against
synthetic peptides that it encodes (Fig. 5). As shown for the
peptide His 80-Cys192, antiserum raised against such peptides
specifically reacted with the ,B-adrenergic receptor. The
reaction was blocked by preincubating the antiserum with the
immunizing peptide but not with a different peptide that is
Peptide pro phe gly ala thr leu vol vol org gly thr pro ieu osn gly ser phe leu
5'-CCT TTC GGC GCC ACC CTG GTG GTG CGC GGC ACC-3
* * * *** *** *
3'-CAC GCG CCG TGG GGA GAC TTG CCG AGG AAG GAC-5'
Peptide 2; ile phe vol tyr leu org vol tyr org glu ala Iys glu gin i/e org lys ile osp org
5'- ATC TTC GTG TAC CTG AGA GTG TAC AGA GAA GCC AA-3'
*3* *-* * -G * * * *3'-CT CTT CGfi TTC CTT GTC TAG TCT TTC TAG CTG TCT-5'
FIG. 2. The nucleotide sequences
of probes based on the amino acid
sequences ofpeptides 1 and 2, chosen
according to chicken codon usage
frequencies (21). Both coding and
noncoding strands were synthesized.
Asterisks 'denote mismatches found
between the probe sequence and the
corresponding cDNA sequence.
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1 10
MetGlyAspGlyTrpLeuProProAspCys'GlyProHisAsnArgSerGly
GGCGGCAGCGGCGGCGGCGCCGCCTTCCTGCCTGCCCGCGGCGCGGCGCGGCCGGAGCGCCCCGCAGCCATGGGCGATGGGTGGCTGCCGCCCGACTGCGGCCCCCACAACCGCTCCGGA
20 30 40 50
G lyG lyGlyA laThrA laA laProThrGlySerArgGl nVa lSerA laGl uLeuLeuSerGl nGl nTrpGl uAlaGlyMetSerLeuLeuMetA laLeu Val Val LeuLeu Il eVa lAl a
1 21 GGCGGCGGGGCGACGGCGGCGCCGACCGGGAGCCGTCAGGTGTCCGCCGAGCTGCTGTCGCAGCAGTGGGAGGCGGGCATGAGCCTGCTGATGGCCCTGGTGGTGCTGCTCATCGTGGCC
60 70 80 90
GlyAsnlalLeuVa1 IleAlaAlalleGlyArgThrGlnArgLeuGlnThrLeuThrAsnLeuPheI leThrSerLeuAlaCysAlaAspLeuValMetGlyLeuLeuVal ValProPhe
241 GGCMACGTGCTGGTGATCGCGGCCATCGGGCGCACGCAGCGGCTGCAGACGCTCACCMACCTCTTCATCACCTCGCTGGCCTGCGCCGACCTGGTGATGGGGCTGCTGGTGGTGCCTTTC
100 110 120 130
G lyA laThrLeu Val ValArgGlyThrTrpLeuTrpGlySerPheLeuCysGl uCysTrpThrSerLeuAspVa lLeuCys Va lThrA laSerlI eG luThrLeuCys ValI lleA laIl e
361 GGGGCCACGCTGGTGGTGCGGGGCACCTGGCTGTGGGGCTCCTTCCTCTGCGAGTGCTGGACATCGCTGGACGTGCTTTGCGTGACGGCAAGCATCGAGACCTTGTGCGTCATCGCCATC361~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
140 150 160 170
AspArgTyrLeuAlalleThrSerProPheArgTyrGlnSerLeuMetThrArgAlaArgAlaLysVal I lleeCysThrValTrpAlalleSerAlaLeuValSerPheLeuProl le
481 GACCGCTACCTGGCCATCACCTCTCCATTCCGCTACCAGAGCCTGATGACCAGGGCTCGGGCCMGGTCATCATCTGCACCGTCTGGGCCATCTCCGCTCTGGTCTCTTTCCTGCCCATC
180 190 200 210
MetMetHisTrpTrpArgAspGluAspProGlnAl aLeuLysCysTyrGlnAspProGlyCysCysAspPheValThrAsnArgAlaTyrAlaI leAlaSerSerI lelleSerPheTyr
601 ATGATGCACTGGTGGCGGGACGAGGACCCTCAGGCGCTCAAGTGCTACCAGGACCCGGGCTGCTGCGACTTTGTCACCAACCGGGCTTACGCCATCGCCTCGTCCATCATCTCCTTCTAC
220 230 240 250
I leProLeuLeu IleMet IlePheVal TyrLeuArgVal TyrArgGl uA laLysGl uGln I leArgLys IlleAspArgCysGl uGlyArgPheTyrGlySerGl nGl uGl nProGl nPro
721 ATCCCCCTCCTCATCATGATCTTCGTGTACCTGCGG6TGTACCGGGAGGCCAAGGAGCAGATCAGGAAGATCGACCGCTGCGAGGGCCGGTTCTATGGCAGCCAGGAGCAGCCGCAGCCA7
260 270 280 290
ProProLeuProGlnHisGlnProI leLeuGlyAsnGlyArgAlaSerLysArgLysThrSerArgValMetAlaMetArgGluHisLysAl aLeuLysThrLeuGlyIleI leMetGly
841 CCCCCGCTCCCCCAACACCAGCCCATCCTCGGCAACGGCCGTGCCAGCMAGAGGAAGACGTCCCGTGTCATGGCCATGAGGGAACACAAAGCTCTGMAGACATTGGGTATCATCATGGGGS3
300 310 320 - - i
Val PheTbrLeuCysTrpLeuProPhePheLeuValAsn I leValAsnValPheAsnArgAspLeuVal ProAspTrpLeuPheVal PhePheAsnTrpLeuGlyTyrAlaAsnSerAla
961 GTGTTCACCCTCTGCTGGCTCCCTTTCTTCITTGGTGAACATTGTCAACGTCTTCAACAGAGATCTGGTGCCGGACTGGCTCTTCGTTTTCTTCAACTGGTTGGGCTACGCCAACTCTGCT961~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
340 350 360 370
PheAsnProIl eleTyrCysArgSerProAspPheArgLysAlaPheLysArgLeuLeuCysPheProArgLysAlaAspArgArgLeuHisAlaGlyGlyGlnProAlaProLeuPro
1081 TTCMCCCCATCATCTACTGCCGCAGCCCAGACTTCCGTMGGCCTTCMGAGGCTGCTCTGCTTCCCCCGCMAGCTGACAGGCGGCTGCACGCCGGCGGCCAACCCGCCCCGCTGCCC
380 390 400 410
GlyGlyPhelleSerThrLeuGlySerProGluHisSerProGlyGlyThrTrpSerAspCysAsnGlyGlyThrArgGlyGlySerGluSerSerLeuGluGluArgHisSerLysThr
1201 GGGGGCTTCATCAGCACCCTGGGCTCCCCTGAGCACAGCCCAGGGGGGACGTGGTCCGACTGCAATGGGGGCACGCGGGGCGGCAGTGAGTCCAGCCTGGAGGAGAGACATAGCMAACA
420 430 440 450
SerArgSerGluSerLysMetGluArgGluLysAsn I leLeuAl aThrThrArgPheTyrCysThrPheLeuGlyAsnGlyAspLysAlaVal PheCysThrValLeuArgI leValLys
1321 TCCCGCTCGGAGTCCMGATGGAGAGGGAAAMCATCCTGGCMCMCMGATTTTACTGCACATTTTTGGGAAATGGCGACMAGCTGTTTTTTGCACAGTATTAAGGATTGTMAG
1441
460 470 480
LeuPheGluAspAlaThrCysThrCysProHisThrHisLysLeuLysMetLysTrpArgPheLysG1nHisGlnAlaEnd
1561 TGAGAGAGTGACTTTTTATATTATTTTATGAAGGTACTGTAAATAGATCCGTATTATAAATTAAAATATCTGAAGGGACTTTATTATTTTTATTTCCAAGTGCCCGCGTGAATCCGCTGT
1681 TATTTTAGCACTTGTGTGTCATTTCCATTCTCCTCTGTGTGTATGTTTTATACCTATTTATACTCTGGTGCAATTTACTACTGTGTAAGTAATTAGTCGATGTGCAATAATGCCATTG
1801 CAGCACAAAAAAAAA
also part of the receptor sequence. Antisera against three
other predicted peptides (Cys244-Pro255, Ala23-Glu34,
Tyr249-Pro265) also reacted specifically with the receptor (not
shown).
The amino terminus of the mature receptor is blocked and
therefore could not be determined directly. If synthesis
originates at the first methionine codon detected, shown as
position 1 in Fig. 4, then the primary translation product has
a molecular weight of 54,078, consistent with the molecular
weight of the turkey erythrocyte ,3adrenergic receptor ac-
cording to polyacrylamide gel electrophoresis in NaDodSO4
(1). The nucleotide sequence surrounding this methionine
codon meets consensus criteria for initiation codons (24). The
amino acid composition of the 40-kDa receptor peptide is
consistent with that predicted by the sequence Met'-Arg350;
Arg350 is a likely hydrophilic site of cleavage during purifi-
cation that would yield a protein of -39.2 kDa. Furthermore,
the sequence Met'-Arg350 predicts that cyanogen bromide
cleavage should produce eight fragments that would contain
more than four amino acids, enough to adhere to the support
in an automatic sequencer. Of these eight, we identified
seven by subjecting a total cyanogen bromide hydrolysate of
the 40-kDa peptide to sequence analysis and monitoring the
appearance of unique predicted residues in the first 18 cycles
of sequencer output. Residues not predicted by these se-
quences were not found. The peptide that was not identified,
and is therefore presumably blocked, was Gly2-Gly43. The
blocked amino terminus of the mature receptor thus lies
between Gly2 and Arg29, the latter being the site of tryptic
cleavage that yielded peptide 5 in Fig. 1.
DISCUSSION
The ,B-adrenergic receptor is an integral membrane glycopro-
tein (1). Hydropathy analysis (ref. 25; results not shown) of
its predicted primary structure revealed the existence of six
highly hydrophobic sequences of23-26 residues each that are
rTAT
FIG. 4. Nucleotide sequence and
deduced amino acid sequence of the
turkey f-adrenergic receptor. Nucle-
otides are numbered at the left, and
amino acids are numbered above the
line, starting at the putative initiation
codon. The locations of the experi-
mentally determined peptide se-
quences are underlined and numbered
according to Fig. 1. The AATAA box
near the 3' end of the cDNA is de-
marcated by a line under the se-
quence, and the potential N-glycosyl-
ation site near the amino terminus is
indicated by a line over the sequence.
potential transmembrane domains. Based on sequence ho-
mology with rhodopsin (to be discussed), we suggest that the
sequence Trp323-Cys3", which is uncharged but less hydro-
phobic, also spans the bilayer. (A charged but slightly
hydrophobic sequence between Ala"7 and Cys' is a less
likely candidate for an eighth membrane span.) A predicted
Pre Anti-I
+I +To
-Top
-45 kDa
_
.31 kDa
-DF
TI,8R M TI OR TI RR 3R
FIG. 5. Immunoblots of purified ,3-adrenergic receptor with
antisera raised against a synthetic peptide encoded by the cDNA.
Purified 0-adrenergic receptor (.R; 200 ng), soy trypsin inhibitor (TI;
100 ng) and a digitonin extract of turkey erythrocyte plasma mem-
branes (M; 2 gg) were electrophoresed and transferred to nitrocel-
lulose paper. Four sets of each sample were run. The first blot was
probed with preimmune serum (Pre) and the second was probed with
antiserum raised against peptide I, His80-Cys192. The third blot was
probed with anti-peptide I serum that had been preabsorbed with
excess peptide I, and the fourth was probed with the same antiserum
that had been preadsorbed with peptide IV, AlaM82-Ile. Soy trypsin
inhibitor monomer (21 kDa) was detected just above the dye front
(DF) and dimer (42 kDa) was observed at approximately the same Rf
as that of the f-adrenergic receptor. After synthesizing peptide I, we
detected the sequence error that alanine was occupying position 5 in
its structure, rather than aspartic acid.
-
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TTATTTGAAGATGCTACTTGCACATGTCCACACACACACAAATTAAAAATGAAATGGAGGTTTAAACAACACCAAGCCTGAAAGTGATCTCTGTTTTTGTCTGATCTGTTATGGGTT
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FIG. 6. Proposed orientation of
the receptor with respect to the plas-
ma membrane bilayer. Membrane-
spanning regions were chosen to in-
clude the maxima in a hydropathy
plot (ref. 25; data not shown) and to
minimize the inclusion ofcharged res-
idues. Assignment of the amino ter-
minus to the extracellular face was
made by analogy to the known orien-
tation of rhodopsin (26), and the as-
signment of the seventh membrane-
spanning region is based on the se-
quence homology with rhodopsin (see
Fig. 5). Positively charged residues,
including histidine, are shown in
squares, and negatively charged res-
idues are shown in circles. The ar-
rangement of hydrophilic sequences
is arbitrary.
arrangement of the 8-adrenergic receptor with respect to the
bilayer is outlined in Fig. 6. By analogy with rhodopsin (26),
we propose that the amino terminus of the receptor, which
contains the only potential N-glycosylation site, is extracel-
lular and that the carboxyl terminus is cytoplasmic.
The P-adrenergic receptor displays overall structural sim-
ilarity to as well as significant sequence homology with
rhodopsin. Both proteins catalyze the activation of a G
protein, either Gs or transducin, in response to a chemical
signal, either a P-adrenergic agonist or trans-retinal (1, 26).
Both proteins are quite hydrophobic, span the bilayer seven
times, have blocked amino termini, and are N-glycosylated at
similar sites near their amino termini (twice in the case of
rhodopsin). This overall arrangement is also displayed by the
receptors for yeast mating factors a and a (27, 28) and by an
oncogene product ofunknown function recently identified by
Young et al. (29). It seems plausible that these proteins may
also regulate G proteins.
Rhodopsin and the p-adrenergic receptor display 22%
identity (Fig. 7), not counting gaps introduced to improve
alignment. This is similar to the homology between
rhodopsins from mammals and Drosophila (31). The only
major structural differences between the receptor and
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rhodopsin are the larger sizes of intracellular loop 5/6 and the
intracellular carboxyl-terminal region of the receptor. Ho-
mology between the avian receptor and rhodopsin is strong-
est in the membrane-spanning sequences, with 28% identity
and numerous conservative substitutions. By contrast,
hydrophilic domains retain only 16% identity. Similarly, the
A-adrenergic receptors from turkey and hamster (7) are also
most homologous in their transmembrane regions, with 76%
identity and 12% highly conservative substitutions (Fig. 7).
The retention of the few charged amino acids and prolines in
the transmembrane sequences is particularly striking. Else-
where in the sequences, average identity between receptors
is only 34%. Although homology between the product of the
mas oncogene (29) and either the ,3adrenergic receptor or
rhodopsin is weak, the homology that exists also lies primar-
ily in the membrane-spanning regions.
The importance of the hydrophobic core of the receptor is
also suggested by its resistance to proteolysis. Treatment of
the receptor with trypsin leaves intact an =19-kDa peptide,
Gln30-Lys'91 or Gln3O-Arg2'O (peptide 5 in Fig. 1). The rest of
the receptor is cleaved to fragments of <10 kDa. Even after
treatment of the receptor with protease sufficient to produce
the 19-kDa fragment, the binding of the f3-adrenergic ligands
Mlm
. M P N
I FIG. 7. Alignment of the amino acid se-
A quences of the turkey erythrocyte f-adrenergic
receptor, hamster lung (7) P32-adrenergic recep-
tor, and bovine rhodopsin (26). The two recep-
tor sequences were aligned according to Lipman
and Pearson (30), and the avian receptor and
R rhodopsin were aligned similarly through Glu236
s in rhodopsin. Because intracellular loop 5/6 is
IE much larger in the receptor than in rhodopsin, a
gap was introduced into the rhodopsin sequence
F at this point, and the sixth and seventh mem-T brane-spanning regions and carboxyl-terminal
regions were then aligned separately. Gaps were
y introduced to optimize alignment of membrane-
D spanning regions and the N-glycosylation sites.
Putative membrane-spanning domains of the
s receptor are marked by solid bars and num-
s bered, and the conserved N-glycosylation site is
marked with an asterisk. Identities between the
A sequence of the avian receptor and either thehamster receptor or rhodopsin are boxed.
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di[PH]hydroalprenolol or ['25I]iodocyanopindolol was dimin-
ished by <20% (not shown). Photoaffinity labeling of the
receptor using [1251I]iodocyanopindolol diazirine also impli-
cates membrane-spanning regions 1-4 in ligand binding
(S.K.-F.W., unpublished data). Thus, most of the hydrophil-
ic regions of the receptor may not be necessary for ligand
binding or maintenance of overall tertiary structure. Because
the 40-kDa amino-terminal fragment of the receptor retains
agonist-stimulated regulatory activity (4, 5), the carboxyl
terminus is not at all required either for ligand binding or for
regulation of G proteins.
Disulfide bonds are evidently involved in the maintenance
of this hydrophobic core. Of 19 cysteine residues, 12 are
found in extracellular domains or within the bilayer, and 9 of
these are conserved in the receptor from hamster lung. Only
1 of the 7 cytoplasmic residues is conserved. A disulfide is
involved in stabilizing peptide 5 (Fig. 1) against proteolysis
(not shown), reduction of disulfides activates the receptor
and sensitizes it to denaturation (ref. 36 and refs. cited
therein), and disulfide bonds are involved in the maintenance
of the receptor's compact structure (32). The p-adrenergic
receptor does not contain a highly crosslinked cysteine-rich
extracellular domain of the sort found in the receptors for
insulin, epidermal growth factor, and low density lipoprotein
(33-35). This mechanism for stabilizing extracellular domains
may not be found in receptors that span the bilayer several
times; they instead may depend upon a hydrophobic core for
stability.
The P-adrenergic receptor can be phosphorylated by sev-
eral protein kinases (ref. 36 and references). The cytoplasmic
loops and the hydroxyl-rich carboxyl-terminal region
(Ser382-Ser422), which is rich in basic and helix-breaking
residues, offer numerous potential phosphorylation sites,
many of which are conserved in the receptor from hamster
lung (7).
The ,-adrenergic receptor and rhodopsin interact with
homologous but nonidentical G proteins. Specificity for
receptors among different G proteins is not absolute (37),
arguing that the G protein-regulating domains on different
receptors will be structurally similar. Based on sequence
homologies between insect and mammalian rhodopsins, it
was suggested (31) that cytoplasmic loop 1/2 of rhodopsin
may be involved in the interaction with transducin. The
corresponding loops in the avian and hamster 3-adrenergic
receptors are quite homologous to each other (6 identities and
2 conservative substitutions in 10 residues) and are weakly
homologous to the same loop in rhodopsin (Fig. 7). Such
conserved sequences are attractive sites for initial genetic
and immunologic investigation of the receptor's regulatory
function.
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